EGFR and non-small cell lung carcinoma: Amivantamab presented preclinical activity against EGFR-mutated NSCLC cells with EGFR-TKIs resistance; importantly, the antitumor efficacy of amivantamab was also observed in two patients with exon20ins, which supports further clinical development [208, 209].